150 related articles for article (PubMed ID: 222523)
1. Inhibition of PHA and NaI04 mitogenesis by the adenosine deaminase inhibitors erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) and 2-deoxycoformycin (2-dCF).
Lum CT; Sutherland DE; Najarian JS
Clin Immunol Immunopathol; 1979 Apr; 12(4):453-9. PubMed ID: 222523
[No Abstract] [Full Text] [Related]
2. Comparison of the activity of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine in vivo.
Plunkett W; Alexander L; Chubb S; Loo TL
Biochem Pharmacol; 1979; 28(2):201-6. PubMed ID: 426835
[No Abstract] [Full Text] [Related]
3. Synergistic effect of 3'-deoxyadenosine N1-oxide and adenosine deaminase inhibitors on growth of Ehrlich ascites tumor cells in vivo.
Svendsen KR; Overgaard-Hansen K; Frederiksen S
Cancer Chemother Pharmacol; 1988; 21(1):35-9. PubMed ID: 3257721
[TBL] [Abstract][Full Text] [Related]
4. Adenosine and hypoxic vasodilatation.
Dóra E
J Cereb Blood Flow Metab; 1985 Dec; 5(4):621-4. PubMed ID: 3877069
[No Abstract] [Full Text] [Related]
5. Suppression of human lymphocyte DNA and protein synthesis in vitro by adenosine and eight modified adenine nucleosides in the presence or in the absence of adenosine deaminase inhibitors, 2'-deoxycoformycin (DCF) and erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA).
Ratech H; Kuritsky L; Thorbecke GJ; Hirschhorn R
Cell Immunol; 1982 Apr; 68(2):244-51. PubMed ID: 6980056
[No Abstract] [Full Text] [Related]
6. Adenosine deaminase inhibitors enhance cerebral anoxic hyperemia in the rat.
Phillis JW; DeLong RE; Towner JK
J Cereb Blood Flow Metab; 1985 Jun; 5(2):295-9. PubMed ID: 3872875
[TBL] [Abstract][Full Text] [Related]
7. In vivo inhibition of adenosine deaminase by 2'-deoxycoformycin in mouse blood and leukemia L1210 cells.
Agarwal RP
Biochem Pharmacol; 1980 Feb; 29(2):187-93. PubMed ID: 6965857
[No Abstract] [Full Text] [Related]
8. Effects of adenosine deaminase inhibitors on lymphocyte-mediated cytolysis.
Wolberg G; Zimmerman TP
Ann N Y Acad Sci; 1985; 451():215-26. PubMed ID: 3878118
[TBL] [Abstract][Full Text] [Related]
9. Hemolysis in mice treated with deoxycoformycin, an inhibitor of adenosine deaminase.
Smith CM; Belch A; Henderson JF
Biochem Pharmacol; 1980 Apr; 29(8):1209-10. PubMed ID: 6966932
[No Abstract] [Full Text] [Related]
10. In vitro effects of adenosine deaminase inhibitors on lymphocyte mitogen responsiveness in the mouse.
Ballow M; Pantschenko AG
Cell Immunol; 1981 Oct; 64(1):29-43. PubMed ID: 6975175
[No Abstract] [Full Text] [Related]
11. Effect of adenosine deaminase inhibitors on the heart's functional and biochemical recovery from ischemia: a study utilizing the isolated rat heart adapted to 31P nuclear magnetic resonance.
Dhasmana JP; Digerness SB; Geckle JM; Ng TC; Glickson JD; Blackstone EH
J Cardiovasc Pharmacol; 1983; 5(6):1040-7. PubMed ID: 6196552
[TBL] [Abstract][Full Text] [Related]
12. Enzyme inhibition titration assay for 2'-deoxycoformycin and its application to the study of the relationship between drug concentration and tissue adenosine deaminase in dogs and rats.
Chassin MM; Adamson RH; Zaharevitz DW; Johns DG
Biochem Pharmacol; 1979 Jun; 28(12):1849-55. PubMed ID: 454456
[No Abstract] [Full Text] [Related]
13. Adenosine deaminase inhibitors. Synthesis of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
Antonini I; Cristalli G; Franchetti P; Grifantini M; Martelli S; Lupidi G; Riva F
J Med Chem; 1984 Mar; 27(3):274-8. PubMed ID: 6699873
[TBL] [Abstract][Full Text] [Related]
14. Effect of chirality in erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) on adenosine deaminase inhibition.
Bessodes M; Bastian G; Abushanab E; Panzica RP; Berman SF; Marcaccio EJ; Chen SF; Stoeckler JD; Parks RE
Biochem Pharmacol; 1982 Mar; 31(5):879-82. PubMed ID: 7082355
[No Abstract] [Full Text] [Related]
15. Inhibition of brain adenosine deaminase by 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl) adenine.
Skolnick P; Nimitkitpaisan Y; Stalvey L; Daly JW
J Neurochem; 1978 Jun; 30(6):1479-82. PubMed ID: 670988
[No Abstract] [Full Text] [Related]
16. Inhibition of human T-cell rosette formation by the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA).
Lum CT; Schmidtke JR; Sutherland DE; Najarian JS
Clin Immunol Immunopathol; 1978 Jul; 10(3):258-61. PubMed ID: 307473
[No Abstract] [Full Text] [Related]
17. Pharmacokinetics of inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl)adenine in CBA mice.
Lambe CU; Nelson DJ
Biochem Pharmacol; 1982 Feb; 31(4):535-9. PubMed ID: 7066021
[TBL] [Abstract][Full Text] [Related]
18. Biochemical basis of the increased activity of 9-beta-D-arabinofuranosyladenine in the presence of inhibitors of adenosine deaminase.
Plunkett W; Alexander L; Chubb S; Loo TL
Cancer Res; 1979 Sep; 39(9):3655-60. PubMed ID: 476690
[No Abstract] [Full Text] [Related]
19. Energy metabolism in adenosine deaminase-inhibited human erythrocytes.
Buc HA; Thuillier L; Hamet M; Garreau F; Moncion A; Pérignon JL
Clin Chim Acta; 1986 Apr; 156(1):61-9. PubMed ID: 3486057
[TBL] [Abstract][Full Text] [Related]
20. Role of nucleoside transport in drug action. The adenosine deaminase inhibitor, deoxycoformycin, and the antiplatelet drugs, dipyridamole and dilazep.
Parks RE; Dawicki DD; Agarwal KC; Chen SF; Stoeckler JD
Ann N Y Acad Sci; 1985; 451():188-203. PubMed ID: 3878117
[No Abstract] [Full Text] [Related]
[Next] [New Search]
